...
search icon
bdtx-img

Black Diamond Therapeutics Inc Share Price

BDTX
NSQ
$2.22
+$0.03
(1.37%)
1D
Industry: Biotechnology Sector: Health Care

Black Diamond Therapeutics Inc Analyst Forecast

Black Diamond Therapeutics Inc Share Price Chart

Black Diamond Therapeutics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$124.78M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
5.9189
Volume info-icon
This is the total number of shares traded during the most recent trading day.
476.98K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
3.36
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.2 L
$4.94 H
$2.22

About Black Diamond Therapeutics Inc, Common Stock

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Black Diamond Therapeutics Inc Stock Returns

Time FrameBDTXSectorS&P500
1-Week Return-2.88%-1.08%-1.38%
1-Month Return-20.36%-0.47%-1.81%
3-Month Return-51.22%2.13%1.38%
6-Month Return-20.94%17.04%5.68%
1-Year Return-6.41%6.56%11.74%
3-Year Return-25%16.78%65.15%
5-Year Return-91.87%34.34%73.68%
10-Year Return-94.45%137.88%260.03%

Black Diamond Therapeutics Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue600.00K2.22M3.24M437.00K343.00K[{"date":"2020-12-31","value":18.53,"profit":true},{"date":"2021-12-31","value":68.47,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":13.5,"profit":true},{"date":"2024-12-31","value":10.59,"profit":true}]
Gross Profit(600.00K)(2.22M)(3.24M)(437.00K)(343.00K)[{"date":"2020-12-31","value":-60000000,"profit":false},{"date":"2021-12-31","value":-221700000,"profit":false},{"date":"2022-12-31","value":-323800000,"profit":false},{"date":"2023-12-31","value":-43700000,"profit":false},{"date":"2024-12-31","value":-34300000,"profit":false}]
Gross Margin-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses69.57M126.87M92.83M86.02M78.78M[{"date":"2020-12-31","value":54.83,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":73.17,"profit":true},{"date":"2023-12-31","value":67.8,"profit":true},{"date":"2024-12-31","value":62.09,"profit":true}]
Operating Income(69.57M)(126.87M)(92.83M)(86.46M)(78.78M)[{"date":"2020-12-31","value":-6957000000,"profit":false},{"date":"2021-12-31","value":-12687200000,"profit":false},{"date":"2022-12-31","value":-9282800000,"profit":false},{"date":"2023-12-31","value":-8646000000,"profit":false},{"date":"2024-12-31","value":-7878100000,"profit":false}]
Total Non-Operating Income/Expense6.36M4.74M3.69M5.94M11.29M[{"date":"2020-12-31","value":56.31,"profit":true},{"date":"2021-12-31","value":42,"profit":true},{"date":"2022-12-31","value":32.69,"profit":true},{"date":"2023-12-31","value":52.64,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(67.25M)(125.60M)(91.17M)(82.44M)(69.68M)[{"date":"2020-12-31","value":-6725400000,"profit":false},{"date":"2021-12-31","value":-12559600000,"profit":false},{"date":"2022-12-31","value":-9116900000,"profit":false},{"date":"2023-12-31","value":-8244200000,"profit":false},{"date":"2024-12-31","value":-6967600000,"profit":false}]
Income Taxes(1.77M)(2.39M)(4.40M)--[{"date":"2020-12-31","value":-177500000,"profit":false},{"date":"2021-12-31","value":-239300000,"profit":false},{"date":"2022-12-31","value":-439900000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(65.48M)(123.20M)(86.77M)--[{"date":"2020-12-31","value":-6547900000,"profit":false},{"date":"2021-12-31","value":-12320300000,"profit":false},{"date":"2022-12-31","value":-8677000000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(67.25M)(125.60M)(91.17M)(82.44M)(69.68M)[{"date":"2020-12-31","value":-6725400000,"profit":false},{"date":"2021-12-31","value":-12559600000,"profit":false},{"date":"2022-12-31","value":-9116900000,"profit":false},{"date":"2023-12-31","value":-8244200000,"profit":false},{"date":"2024-12-31","value":-6967600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(67.25M)(125.60M)(91.17M)(82.44M)(69.68M)[{"date":"2020-12-31","value":-6725400000,"profit":false},{"date":"2021-12-31","value":-12559600000,"profit":false},{"date":"2022-12-31","value":-9116900000,"profit":false},{"date":"2023-12-31","value":-8244200000,"profit":false},{"date":"2024-12-31","value":-6967600000,"profit":false}]
EPS (Diluted)(2.05)(3.47)(2.52)(1.88)(1.27)[{"date":"2020-12-31","value":-205,"profit":false},{"date":"2021-12-31","value":-347,"profit":false},{"date":"2022-12-31","value":-252,"profit":false},{"date":"2023-12-31","value":-188,"profit":false},{"date":"2024-12-31","value":-126.53,"profit":false}]

Black Diamond Therapeutics Inc Ratios

Black Diamond Therapeutics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

BDTX
Cash Ratio 8.72
Current Ratio 8.94

Black Diamond Therapeutics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BDTX
ROA (LTM) 6.26%
ROE (LTM) 19.23%

Black Diamond Therapeutics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BDTX
Debt Ratio Lower is generally better. Negative is bad. 0.20
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.80

Black Diamond Therapeutics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BDTX
Trailing PE 5.92
Forward PE 8.33
P/S (TTM) 1.78
P/B 1.00
Price/FCF NM
EV/R 0.16
EV/Ebitda 0.90

FAQs

What is Black Diamond Therapeutics Inc share price today?

Black Diamond Therapeutics Inc (BDTX) share price today is $2.22

Can Indians buy Black Diamond Therapeutics Inc shares?

Yes, Indians can buy shares of Black Diamond Therapeutics Inc (BDTX) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BDTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Black Diamond Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Black Diamond Therapeutics Inc (BDTX) via the Vested app. You can start investing in Black Diamond Therapeutics Inc (BDTX) with a minimum investment of $1.

How to invest in Black Diamond Therapeutics Inc shares from India?

You can invest in shares of Black Diamond Therapeutics Inc (BDTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in BDTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Black Diamond Therapeutics Inc shares
What is Black Diamond Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Black Diamond Therapeutics Inc (BDTX) is $4.94. The 52-week low price of Black Diamond Therapeutics Inc (BDTX) is $1.2.

What is Black Diamond Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Black Diamond Therapeutics Inc (BDTX) is 5.9189

What is Black Diamond Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Black Diamond Therapeutics Inc (BDTX) is 1.00

What is Black Diamond Therapeutics Inc dividend yield?

The dividend yield of Black Diamond Therapeutics Inc (BDTX) is 0.00%

What is the Market Cap of Black Diamond Therapeutics Inc?

The market capitalization of Black Diamond Therapeutics Inc (BDTX) is $124.78M

What is Black Diamond Therapeutics Inc's stock symbol?

The stock symbol (or ticker) of Black Diamond Therapeutics Inc is BDTX

How Can Investors Use Black Diamond Therapeutics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Black Diamond Therapeutics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Black Diamond Therapeutics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Black Diamond Therapeutics Inc shares for Indian investors?

When investing in Black Diamond Therapeutics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Black Diamond Therapeutics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Black Diamond Therapeutics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Black Diamond Therapeutics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Black Diamond Therapeutics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top